Back to Search
Start Over
New-Onset of Inflammatory Bowel Disease in a Patient Treated With Teprotumumab for Thyroid Associated Ophthalmopathy
- Source :
- Ophthalmic Plastic & Reconstructive Surgery. 37:e160-e164
- Publication Year :
- 2021
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2021.
-
Abstract
- A patient with thyroid-associated ophthalmopathy was treated with teprotumumab and developed symptoms concerning for inflammatory bowel disease after her sixth infusion. Colonoscopy was performed, and mucosal biopsies identified evidence of active colitis consistent with a diagnosis of ulcerative colitis. Despite treatment with budesonide and mesalamine, the patient continued to be symptomatic one and a half months after cessation of teprotumumab and required infliximab to achieve good control of her inflammatory bowel disease. This case represents the first report of new-onset inflammatory bowel disease arising during treatment with teprotumumab.
- Subjects :
- Budesonide
medicine.medical_specialty
medicine.diagnostic_test
Teprotumumab
business.industry
Colonoscopy
General Medicine
medicine.disease
Inflammatory bowel disease
Gastroenterology
Ulcerative colitis
Infliximab
03 medical and health sciences
Ophthalmology
0302 clinical medicine
Internal medicine
030221 ophthalmology & optometry
medicine
Surgery
Colitis
business
Thyroid-Associated Ophthalmopathy
medicine.drug
Subjects
Details
- ISSN :
- 07409303
- Volume :
- 37
- Database :
- OpenAIRE
- Journal :
- Ophthalmic Plastic & Reconstructive Surgery
- Accession number :
- edsair.doi...........7a80bc7fec5544c30de12dabd8f396eb
- Full Text :
- https://doi.org/10.1097/iop.0000000000001943